Galectin Therapeutics
7 Wells Avenue
Suite #34
Newton
Massachusetts
02459
United States
Tel: 617-559-0033
Fax: 617-928-3450
Website: http://www.galectintherapeutics.com/
234 articles about Galectin Therapeutics
-
Galectin Therapeutics Expands Clinical Team with the Appointment of Khurram Jamil, M.D. as Vice President, Clinical Development
3/12/2024
Galectin Therapeutics, Inc. today announced the appointment of Khurram Jamil, M.D. as Vice President, Clinical Development.
-
UPDATE – Galectin Therapeutics Reports Financial Results for the Quarter Ended September 30, 2023 and Provides Business Update
11/13/2023
Galectin Therapeutics, Inc. reported financial results and provided a business update for the three months ended September 30, 2023.
-
Galectin Therapeutics Reports Financial Results for the Quarter Ended September 30, 2023 and Provides Business Update
11/13/2023
Galectin Therapeutics, Inc., the leading developer of therapeutics that target galectin proteins, reported financial results and provided a business update for the three months ended September 30, 2023.
-
Galectin Therapeutics to Share Five Scientific Presentations at The Liver Meeting™ 2023, Hosted by the AASLD
11/3/2023
Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin-3, today announced that it will share five scientific presentations at The Liver Meeting™ 2023, hosted by the American Association for the Study of Liver Diseases (AASLD). The Liver Meeting™ will be held November 10-14, 2023, in Boston, Mass.
-
Galectin Therapeutics to Participate in the H.C. Wainwright 7th Annual NASH Investor Conference on October 24, 2023
10/23/2023
Galectin Therapeutics Inc. announced today the Company will be participating in the H.C. Wainwright 7th Annual NASH Investor Conference being held virtually on October 24, 2023.
-
Galectin Therapeutics Announces Nomination of Dr. Benjamin S. Carson, Sr. to Board of Directors
10/12/2023
Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, announced today that Dr. Benjamin S. Carson, Sr. has been nominated to serve on the company’s board of directors.
-
Galectin Therapeutics Reports the Positive Outcome of the Fourth Data and Safety Monitoring Board Meeting for NAVIGATE, its Seamless, Adaptive Phase 2b/3 Study of Belapectin
10/3/2023
Galectin Therapeutics, Inc. today reported the positive outcome of its fourth data and safety monitoring board (DSMB) meeting for NAVIGATE, its seamless, adaptive, Phase 2b/3 study of belapectin in patients with portal hypertension caused by non-alcoholic steatohepatitis (NASH) liver cirrhosis.
-
Galectin Therapeutics to Present Update on its Belapectin Liver Cirrhosis Program at the 20th Edition of Discovery on Target meeting, in Boston, September 25-28, 2023
9/26/2023
Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin-3, today announced it will participate in the 20th edition of the Discovery on Target meeting, the industry’s preeminent event on Novel Drug Targets and Technologies.
-
Galectin Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference on September 13, 2023
9/11/2023
Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, announced today the Company will be participating in the H.C. Wainwright 25th Annual Global Investment Conference being held on September 11-13, 2022.
-
Galectin Therapeutics to Present Data on Liver Cirrhosis at the 9th Edition of the Paris NASH meeting, at Institut Pasteur, September 7th & 8th 2023
9/7/2023
Galectin Therapeutics Inc. (NASDAQ: GALT) announced today the Company will participate in the 9th Edition of the Paris NASH meeting, where a select group of international experts gather each year at the prestigious Institut Pasteur in Paris to discuss the latest scientific and clinical research developments in non-alcoholic steatohepatitis (NASH) and its complications, including liver cirrhosis.
-
Galectin Therapeutics Reports Financial Results for the Quarter Ended June 30, 2023 and Provides Business Update
8/14/2023
Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the three months ended June 30, 2023.
-
Galectin Therapeutics Reports Financial Results for the Quarter Ended March 31, 2023 and Provides Business Update
5/15/2023
Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the three months ended March 31, 2023.
-
Galectin Therapeutics to Participate in the H.C. Wainwright BioConnect Investment Conference May 2, 2023
4/27/2023
Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, announced today the Company will be participating in the H.C. Wainwright BioConnect Investment Conference on Tuesday, May 2, 2023.
-
Galectin Therapeutics’ Statement Following the Recent 2023 Emerging Topic Conference on NASH Cirrhosis, Sponsored by the American Association for the Study of Liver Diseases
4/18/2023
Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, attended the 2023 Emerging Topic Conference on NASH Cirrhosis: From Mechanisms to Management, sponsored by the American Association for the Study of Liver Diseases (AASLD)
-
Galectin Therapeutics Reports 2022 Financial Results and Provides Business Update
3/30/2023
Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the year ended December 31, 2022.
-
Galectin Therapeutics Provides Final Randomization Status of NAVIGATE, its Seamless, Adaptive Phase 2b/3 Study of Belapectin in Patients with Liver Cirrhosis Caused by Non-Alcoholic Steatohepatitis
3/2/2023
Galectin Therapeutics, Inc. announced that in late December 2022, it ended the enrollment of new patients into NAVIGATE, its seamless, adaptive, phase 2b/3 study of belapectin in patients with liver cirrhosis caused by non-alcoholic steatohepatitis (NASH).
-
Galectin Therapeutics contribution to improve histology interpretation of cirrhotic liver biopsies with Machine Learning published in prominent Gastroenterology Journal
1/24/2023
Galectin Therapeutics Inc. announced that the scientific paper, “Machine Learning Liver Histology Scores Correlate With Portal Hypertension Assessments In Nonalcoholic Steatohepatitis Cirrhosis,” was published in Alimentary Pharmacology and Therapeutics, a prominent peer-reviewed gastroenterology journal.
-
Galectin Therapeutics Announces the End of Enrollment of NAVIGATE, its Seamless, Adaptive Phase 2b/3 Study of Belapectin in Patients with Liver Cirrhosis Caused by Non-Alcoholic Steatohepatitis
1/5/2023
Galectin Therapeutics, Inc. announced that in late December 2022, it ended enrollment of NAVIGATE, its seamless, adaptive, phase 2b/3 study of belapectin in patients with liver cirrhosis caused by non-alcoholic steatohepatitis.
-
Galectin Therapeutics to Webcast Corporate Update on December 1, 2022 after Annual Meeting of Stockholders
11/29/2022
Galectin Therapeutics Inc.(NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, announced today that management will present a corporate update via live webcast immediately following the business portion of its 2022 Annual Meeting of Stockholders to be held on Thursday, December 1, 2022 beginning at 11:00 a.m. ET.
-
Galectin Therapeutics to Present at 6th Obesity & NASH Drug Development Summit
11/28/2022
Galectin Therapeutics Inc. announced today the Company will be presenting at the 6 th Obesity and NASH Drug Development Summit in Boston, MA.